Long-Term Results of Combination Chemotherapy with or without Irradiation in Small Cell Lung Cancer: A 5- to 11-Year Follow-Up.

Abstract

patients with newly diagnosed small cell lung cancer (SCLC) were treated using combination chemotherapy with or without thoracic irradiation and prophylactic cranial irradiation (PCI) in a series of cooperative therapeutic trials. With a minimumfollow-up of 4.7 years, 13 (9%) patients survived and were free of SCLC. These included ll (15%) of 76 patients with limited disease and two (3%) of 72 patients with extensive disease. Three died without any evidence of SCLC(one each from second leukemia, non-small cell lung cancer, and unrelated disease). The remaining 10 (7%) patients are currently alive and free of SCLCbeyond 4.7 years. Since late relapse beyond 5 years is a very rare event, these patients may have been cured. However, late toxicity of PCI must be kept in mind. Three amongthe 10 patients have suffered from neuropsychologic symptoms of varying degrees in severity. Although the long-term survival rate is a benchmark in the treatment of SCLC, modifications of therapy that may potentially avoid such toxicities should be considered hereafter.

Estimating the risk of developing secondary hematologic malignancies in patients with T1/T2 prostate cancer undergoing diverse treatment modalities: A large population‐based study

“…5,6 However, it was frequently reported that RT is associated with a high risk of secondary hematologic malignancies (SHMs) in patients with diverse types of cancer. [7][8][9][10][11][12] This can be related to the fact that RT enhances the fitness of clonal hematopoietic stem cells, which can influence outcome through progression to hematologic malignancies and through cell nonautonomous effects on solid tumors. 13,14 Although a number of scholars have concentrated on the association between RT and development of SHMs in patients with early-stage PC, few researches have investigated the risk of developing SHMs in such patients undergoing various therapies.…”

“…The PC‐specific survival of patients who underwent RT has markedly attracted scholars’ attention 5,6 . However, it was frequently reported that RT is associated with a high risk of secondary hematologic malignancies (SHMs) in patients with diverse types of cancer 7–12 . This can be related to the fact that RT enhances the fitness of clonal hematopoietic stem cells, which can influence outcome through progression to hematologic malignancies and through cell nonautonomous effects on solid tumors 13,14 …”